Legionella und Legionellose

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung

Beitragende

  • Martin Kolditz - , Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus Dresden (Autor:in)
  • Christian Lück - , Institut für Medizinische Mikrobiologie und Virologie, Universitätsklinikum Carl Gustav Carus Dresden (Autor:in)

Abstract

Diagnosed and reported Legionella pneumonias are slightly increasing during recent years. This might at least partially be due to more frequently used diagnostic tests.In severe pneumonia, nucleic acid amplification based methods should supplement the L. pneumophila serogroup-1 urinary antigen test because of their improved spectrum and sensitivity.Recent in vitro data suggest enhanced efficacy of levofloxacin when compared to macrolides. This complements recent clinical cohort data. Thus levofloxacin (750-1000 mg/d) is regarded the treatment of choice for confirmed legionellosis. Second line options are azithromycin or moxifloxacin. Treatment duration of 7 days should be sufficient in most cases.Development of resistance is rare and no routine resistance testing is necessary.

Details

OriginalspracheDeutsch
Seiten (von - bis)1030-1033
Seitenumfang4
FachzeitschriftDeutsche medizinische Wochenschrift (1946)
Jahrgang144
Ausgabenummer15
PublikationsstatusVeröffentlicht - Aug. 2019
Peer-Review-StatusJa

Externe IDs

ORCID /0000-0001-6022-6827/work/127321420
Scopus 85069809583

Schlagworte

Schlagwörter

  • Anti-Bacterial Agents/pharmacology, Drug Resistance, Bacterial, Humans, Legionella/drug effects, Legionellosis/diagnosis, Levofloxacin/pharmacology